Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD18 PET-adapted first-line therapy trial for advanced Hodgkin lymphoma
NL-OMON46958Phase 3Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and BEACOPP in Hodgkin lymphoma (HL) (4 arms), sponsored by Vrije University Medical Center. Primary endpoint: Progression-free survival. Started Nov 2009; status: active, not recruiting.
02
Drugs
rituximabBEACOPP
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON46958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46958.